Department of plastic surgery, The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, Dalian, 116011, China.
School of Chemical Engineering, Dalian University of Technology, No. 2 Linggong Road, Dalian, 116024, China.
Cell Tissue Bank. 2021 Mar;22(1):77-91. doi: 10.1007/s10561-020-09867-8. Epub 2020 Nov 20.
Exosomes exhibit great therapeutic potential in bone tissue engineering. The study aimed to investigate whether the exosomes derived from human adipose-derived stem cells (hADSCs-Exos) during different time-span of osteogenic differentiation could promote osteogenesis. The appropriate concentrations of hADSCs-Exos to enhance the proliferation, migration and osteogenesis of hADSCs-Exos were also examined. PKH67 labelled hADSCs-Exos was used to detect the internalization ability of hADSCs. The osteogenic differentiation abilities of hADSCs after treatment with hADSCs-Exos was evaluated by Alizarin red staining (ARS). The proliferation and migration of hADSCs was examined by cell counting kit-8 and wound healing assay, respectively. The expression of exosomal surface markers and osteoblast-related protein of hADSCs was assessed by Western blot. PKH67-labelled exosomes were internalized by hADSCs after 4 h incubation. ARS showed that the amount of mineralized nodules in Exo group was significantly higher than that in Exo group. hADSCs-Exos could promote the proliferation and migration capacity of hADSCs. Western blot analysis showed that after hADSCs-Exos treatment, ALP and RUNX2 were significantly enhanced. Specially, the Exo group of 15 μg/mL significantly upregulated the expression of RUNX2 than the other exosomes treated groups. Our findings suggest that exosomes secreted by hADSCs during osteogenic induction for 1-14 days could be efficiently internalized by hADSCs and could induce osteogenic differentiation of hADSCs. Moreover, administration of Exo at 15 μg/mL promoted the proliferation and migration of hADSCs. In conclusion, our research confirmed that comprised of hADSCs-Exos and hADSCs may provide a new therapeutic paradigm for bone tissue engineering.
外泌体在骨组织工程中具有巨大的治疗潜力。本研究旨在探讨人脂肪来源干细胞(hADSCs)在成骨分化不同时间跨度中分泌的外泌体(hADSCs-Exos)是否能促进成骨。还研究了合适浓度的 hADSCs-Exos 来增强 hADSCs-Exos 的增殖、迁移和成骨能力。PKH67 标记的 hADSCs-Exos 用于检测 hADSCs 的内化能力。通过茜素红染色(ARS)评估 hADSCs 经 hADSCs-Exos 处理后的成骨分化能力。通过细胞计数试剂盒-8 和划痕愈合试验分别检测 hADSCs 的增殖和迁移。通过 Western blot 评估 hADSCs 外泌体表面标志物和成骨相关蛋白的表达。PKH67 标记的外泌体在孵育 4 h 后被 hADSCs 内化。ARS 显示,外泌体组的矿化结节数量明显高于外泌体组。hADSCs-Exos 能促进 hADSCs 的增殖和迁移能力。Western blot 分析显示,经 hADSCs-Exos 处理后,ALP 和 RUNX2 表达明显增强。特别是,15μg/mL 的外泌体组显著上调了 RUNX2 的表达,高于其他外泌体处理组。我们的研究结果表明,hADSCs 在成骨诱导的 1-14 天期间分泌的外泌体可以被 hADSCs 有效内化,并能诱导 hADSCs 的成骨分化。此外,15μg/mL 的外泌体促进了 hADSCs 的增殖和迁移。总之,我们的研究证实了由 hADSCs-Exos 和 hADSCs 组成的复合物可能为骨组织工程提供一种新的治疗范例。